GGrantIndex
← Leaderboards

Michael L. Hutton

Mayo Clinic Coll Of Med, Jacksonville

$5,237,431
Attributed
$5,237,431
Total exposure
8
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.4M · FY200509
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$13,009,556 · 9

By mechanism

P01$9,504,002 · 4
R01$2,580,065 · 4
P50$925,489 · 1

Top collaborators

No co-investigators on record.

Most similar at Mayo Clinic Coll Of Med, Jacksonville

Same institution · by research overlap

Others in their field

Top investigators on “Tau Proteins

Research focus

Tau ProteinsNeuropathologyLaboratory MouseNeural DegenerationGenetically Modified AnimalsNeurofibrillary TanglesAgingNeuronsNeurogeneticsComplementary DnaPathologic ProcessImmunocytochemistryPhenotypeTransgenic OrganismsMouse ModelHuman Genetic Material TagDementiaLesionPhosphorylationReportingGenesGene MutationParkinson'S DiseaseAlzheimer'S Disease

Grant awards (34)

ROLE OF THE HSP70/CHIP CHAPERONE SYSTEM IN TAU BIOLOGY AND PATHOGENESIS$281,412
P01 · FY2009 · AG · contact PI
ROLE OF THE HSP70/CHIP CHAPERONE SYSTEM IN TAU BIOLOGY AND PATHOGENESIS$274,534
P01 · FY2008 · AG · contact PI
Genetics of Frontotemporal Dementia (FTD) and Motor Neuron Disease$190,140
P50 · FY2008 · AG · contact PI
ROLE OF THE HSP70/CHIP CHAPERONE SYSTEM IN TAU BIOLOGY AND PATHOGENESIS$308,374
P01 · FY2007 · AG · contact PI
Genetics of Frontotemporal Dementia (FTD) and Motor Neuron Disease$181,649
P50 · FY2007 · AG · contact PI
Tau and Neurodegeneration II: A therapeutic target$39,968
P01 · FY2007 · AG · contact PI
Tau and Neurodegeneration II: A therapeutic target$1,286,955
P01 · FY2006 · AG · contact PI
Amyloid and tau pathology in a transgenic model$288,732
R01 · FY2006 · AG · contact PI
ROLE OF THE HSP70/CHIP CHAPERONE SYSTEM IN TAU BIOLOGY AND PATHOGENESIS$284,617
P01 · FY2006 · AG · contact PI
The genetics of chromosome 17q21-linked tau-negative FTD$193,800
R01 · FY2006 · AG · contact PI
GENETICS OF FTD AND MOTOR NEURON DISEASE$188,997
P50 · FY2006 · AG · contact PI
Tau and Neurodegeneration II: A therapeutic target$1,302,269
P01 · FY2005 · AG
Amyloid and tau pathology in a transgenic model$295,680
R01 · FY2005 · AG
ROLE OF THE HSP70/CHIP CHAPERONE SYSTEM IN TAU BIOLOGY AND PATHOGENESIS$278,035
P01 · FY2005 · AG
Tangle Formation in P301L Transgenic Mice$235,500
R01 · FY2005 · AG
GENETICS OF FTD AND MOTOR NEURON DISEASE$184,523
P50 · FY2005 · AG
ADMINISTRATIVE AND STATISTICAL ANALYSIS CORE$59,923
P01 · FY2005 · AG
Amyloid and tau pathology in a transgenic model$295,680
R01 · FY2004 · AG
Tangle Formation in P301L Transgenic Mice$235,500
R01 · FY2004 · AG
GENETICS OF FTD AND MOTOR NEURON DISEASE$180,180
P50 · FY2004 · AG
TAU AND NEURODEGENERATION$1,309,657
P01 · FY2003 · AG
Amyloid and tau pathology in a transgenic model$295,680
R01 · FY2003 · AG
Tangle Formation in P301L Transgenic Mice$235,500
R01 · FY2003 · AG
TAU AND NEURODEGENERATION$1,274,501
P01 · FY2002 · AG
Tangle Formation in P301L Transgenic Mice$235,500
R01 · FY2002 · AG
ANALYSIS OF THE ROLE OF 3 AND 4 REPEAT TAU IN VITRO AND IN VIVO$0
P01 · FY2002 · AG
TAU AND NEURODEGENERATION$1,240,362
P01 · FY2001 · AG
TAU AND NEURODEGENERATION$111,182
P01 · FY2001 · AG
ANALYSIS OF THE ROLE OF 3 AND 4 REPEAT TAU IN VITRO AND IN VIVO$0
P01 · FY2001 · AG
ANALYSIS OF THE ROLE OF 3 AND 4 REPEAT TAU IN VITRO AND IN VIVO$0
P01 · FY2001 · AG
TAU AND NEURODEGENERATION$1,207,231
P01 · FY2000 · AG
ANALYSIS OF THE ROLE OF 3 AND 4 REPEAT TAU IN VITRO AND IN VIVO$244,982
P01 · FY2000 · AG
IDENTIFICATION OF THE GENE FOR FTDP ON CHROMOSOME 17$191,993
R01 · FY2000 · NS
IDENTIFICATION OF THE GENE FOR FTDP ON CHROMOSOME 17$76,500
R01 · FY2000 · NS